Loading patent…
OwnerKazuhiko Imakawa, Kentaro Nagaoka +1inventors
InventorsKazuhiko Imakawa, Kentaro Nagaoka, Fumiko Watanabe
Estimating the term…
For a pregnancy to be established, communication between conceptus and mother, and implantation of the conceptus on the uterine wall must occur. If a factor mediating the communication between conceptus and mother is investigated and the factor can be used to control the communication, it may be possible to develop a method for treating a disorder such as sterility or preventive measures. Contraception in a safe manner may also be provided. IP-10, which is known as a protein of 10 kDa usually induced by interferon-γ is identified as a factor that controls implantation of conceptus on the uterine wall through involving immune responses and activation of conceptus migration during an implantation period, the promotion of implantation of conceptus to the uterine wall, and chemotactic activity. Based on these finding, an agent for treating sterility, promoting pregnancy, inducing implantation of conceptus on the uterine wall, or controlling interaction between conceptus and mother is provided.
A pharmaceutical drug and/or veterinary drug comprising an effective amount of one or more members selected from the group consisting of an IP-10 protein, and IP-10 analogues and IP-10 derivatives having at least a deletion, addition, and/or substitution of one or more amino acid residues in IP-10 and having a biological activity essentially equal or equivalent to that of intact IP-10,
A method for obtaining a biological activity selected from the group consisting of (a) activation of conceptus migration, (b) promotion of conceptus implantation on the uterine wall, (c) treatment of sterility, (d) promotion of pregnancy, (e) control of interaction between conceptus and maternal system, (f) activation of immunocyte migration, and (g) control of immune function in the uterus,
An assay for measuring an IP-10 activity to determine a biological activity selected from the group consisting of (a) activation of conceptus migration, (b) promotion of conceptus implantation on the uterine wall, (c) treatment of sterility, (d) promotion of pregnancy, (e) control of interaction between conceptus and maternal system, (f) activation of immunocyte migration, and (g) control of immune function in the uterus.
A pharmaceutical drug and/or veterinary drug comprising a nucleic acid having a nucleotide sequence encoding a member selected from the group consisting of IP-10, and IP-10 analogues and IP-10 derivatives having at least a deletion, addition, and/or substitution of one or more amino acid residues in IP-10 and having a biological activity essentially equal or equivalent to that of intact IP-10,
A pharmaceutical drug and/or veterinary drug comprising a nucleic acid selected from the group consisting of
A pharmaceutical drug comprising a compound, or a salt thereof, for promoting or inhibiting a biological activity selected from the group consisting of (a) activation of conceptus migration, (b) promotion of conceptus implantation on the uterine wall, (c) treatment of sterility, (d) promotion of pregnancy, (e) control of interaction between conceptus and maternal system, (f) activation of immunocyte migration, and (g) control of immune function in the uterus,
A method or kit for screening a compound promoting or inhibiting a biological activity owned by a member selected from the group consisting of IP-10, IP-10 analogues and IP-10 derivatives having at least a deletion, addition, and/or substitution of one or more amino acid residues in IP-10 and having a biological activity essentially equal or equivalent to that of intact IP-10, or salts thereof, and IP-10 nucleic acids encoding the same, wherein the biological activity is selected from the group consisting of (a) activation of conceptus migration, (b) promotion of conceptus implantation on the uterine wall, (c) treatment of sterility, (d) promotion of pregnancy, (e) control of interaction between conceptus and maternal system, (f) activation of immunocyte migration, and (g) control of immune function in the uterus,
A reagent for detecting the presence of a mutated portion capable of altering the activity or expression of IP-10 wherein said mutated portion is present in IP-10, a gene encoding IP-10, or the corresponding RNA, and genetically diagnosing a disease associated with IP-10.
A method for genetic diagnosis of a disease associated with an IP-10 gene which comprises the steps of;
A method for determining or diagnosing a biological activity in a specimen which comprises quantitating an IP-10 polynucleotide present in the specimen and using as an indicator the IP-10 polynucleotide amount to determine or diagnose a biological activity level in the specimen
A method for determining or diagnosing a biological activity in a specimen which comprises quantitating an IP-10 protein present in the specimen and using as an indicator the IP-10 protein amount to determine or diagnose a biological activity level in the specimen
A composition for determining or diagnosing a biological activity in a specimen which comprises at least a member selected from an oligonucleotide or polynucleotide which hybridizes with IP-10 polynucleotide under a stringent condition,
A nucleic acid array for determining or diagnosing a biological activity level in a specimen which comprises (i) an oligonucleotide or polynucleotide which hybridizes with IP-10 polynucleotide under a stringent condition or (ii) IP-10 polynucleotide,
A primer set used for PCR-amplification of IP-10 polynucleotide in a specimen and determining or diagnosing the degree of a biological activity of a specimen,
A diagnosis kit for determining or diagnosing the degree of a biological activity of a specimen comprising at least one antibody capable of recognizing IP-10,
A diagnosis kit for determining or diagnosing the degree of a biological activity of a specimen comprising at least elements consisting of (i) an immobilized antibody capable of recognizing IP-10, and (ii) an antibody capable of recognizing an IP-10 epitope other than that being recognized by the antibody (i),
A method for measuring the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A method for measuring the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A method for measuring the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A method for measuring the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A method for measuring the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A method for measuring or diagnosing the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
A reagent for measuring or diagnosing the degree of abnormality or its risk associated with a biological activity selected from the group consisting of:
Dependencies are inferred from the claim text.